Tyra Biosciences, Inc. (TYRA) — 8-K Filings

8-K Filings (15)

• Tyra Biosciences Appoints New Chief Medical Officer — Apr 17, 2026 Risk: medium
  On April 16, 2026, Tyra Biosciences, Inc. filed an 8-K report detailing the departure of Dr. Todd Manetta from his role as Chief Medical Officer. The filing als
• Tyra Biosciences Appoints New Chief Medical Officer — Apr 2, 2026 Risk: medium
  On April 2, 2026, Tyra Biosciences, Inc. filed an 8-K report detailing changes in its executive officers. Specifically, the filing announced the appointment of
• Tyra Biosciences Files 8-K on Leadership and Compensation Changes — Dec 1, 2025 Risk: medium
  On November 25, 2025, Tyra Biosciences, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing
• Tyra Biosciences Files 8-K on Financials — Nov 5, 2025 Risk: low
  Tyra Biosciences, Inc. filed an 8-K on November 5, 2025, reporting on its results of operations and financial condition. The filing includes financial statement
• Tyra Biosciences Appoints New Chief Medical Officer — Aug 22, 2025 Risk: medium
  On August 21, 2025, Tyra Biosciences, Inc. announced the appointment of Dr. Todd M. W. Green as Chief Medical Officer. Dr. Green brings extensive experience in
• Tyra Biosciences Files 8-K Report — Jun 30, 2025 Risk: medium
  On June 30, 2025, Tyra Biosciences, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure, with no specific details pr
• Tyra Biosciences Files 8-K on Security Holder Vote Matters — May 29, 2025 Risk: low
  Tyra Biosciences, Inc. filed an 8-K on May 29, 2025, to report on the submission of matters to a vote of its security holders. The filing does not disclose spec
• Tyra Biosciences Appoints New Director, Adjusts Executive Pay — Jan 29, 2025 Risk: low
  On January 28, 2025, Tyra Biosciences, Inc. announced changes to its board of directors and executive compensation. Specifically, Dr. Jeffrey W. Chen was appoin
• Tyra Biosciences Files 8-K Report — Oct 28, 2024 Risk: medium
  On October 28, 2024, Tyra Biosciences, Inc. filed an 8-K report. The filing indicates an "Other Events" item, but the specific details of this event are not ela
• Tyra Biosciences Appoints New CMO, Adds Directors — Oct 25, 2024 Risk: medium
  Tyra Biosciences, Inc. announced on October 24, 2024, a series of significant executive and board changes. These include the appointment of Dr. Todd W. P. Brach
• Tyra Biosciences Reports Unregistered Equity Sales — Oct 18, 2024 Risk: medium
  On October 18, 2024, Tyra Biosciences, Inc. filed an 8-K report detailing unregistered sales of equity securities. The filing indicates that the company engaged
• Tyra Biosciences Holds Annual Meeting, Elects Directors — May 31, 2024 Risk: low
  On May 29, 2024, Tyra Biosciences, Inc. filed an 8-K report detailing several key events. The company announced the results of its annual meeting of stockholder
• Tyra Biosciences Appoints New CMO, Adopts Equity Plan — May 7, 2024 Risk: medium
  Tyra Biosciences, Inc. announced on May 4, 2024, changes in its board of directors and executive compensation. Specifically, Dr. Jeffrey W. Tobias has been appo
• Tyra Biosciences Sells Unregistered Equity, Secures New Funding — Feb 5, 2024
  Tyra Biosciences, Inc. filed an 8-K on February 5, 2024, reporting an "Entry into a Material Definitive Agreement" and "Unregistered Sales of Equity Securities"
• TYRA Biosciences Files 8-K for 'Other Event', Confirms Emerging Growth Status — Feb 1, 2024
  Tyra Biosciences, Inc. filed an 8-K on February 1, 2024, to report an "Other Event." This filing primarily serves to update the public record with basic company

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX